The Board of Directors of Paushak Limited, an Alembic Group company, met on January 27, 2026, to approve the unaudited financial results for the quarter and nine months ended December 31, 2025. For the quarter ended December 31, 2025, the company reported a total income of ₹49.77 crores, reflecting a decline from both the previous quarter’s ₹59.83 crores and the corresponding quarter of the previous year’s ₹55.57 crores. Net profit for the period stood at ₹6.17 crores, a significant drop of approximately 28.34% compared to the September 2025 quarter (₹8.61 crores) and a 59.57% decline compared to the ₹15.26 crores reported in the quarter ended December 31, 2024.

Paushak Limited is India’s largest specialty phosgene-based chemical manufacturer and a key member of the 118-year-old Alembic Group. The company specializes in producing phosgene gas and a wide range of derivatives, including isocyanates, chloroformates, and carbamates, which serve the pharmaceutical, agrochemical, and performance industries. In recent developments during 2025, the company announced a 3:1 bonus issue and a stock split in August to reward shareholders. Additionally, in January 2026, Paushak announced the commencement of commercial production at its new multi-purpose manufacturing plant, following a strategic investment of approximately ₹175 crores aimed at enhancing production capacity and operational flexibility. While promoters like Chirayu Ramanbhai Amin hold a significant majority of 67.28% in the company, retail and public investors account for the remaining shareholding as of December 2025.